OLIGOPELVIS 2-GETUG P12- elective nodal radiotherapy for oligorecurrent pelvic/para-aortic nodes in prostate cancer: early toxicity of a randomized phase 3 trial.

Fiche publication

Date publication

avril 2027

Journal

Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology

Auteurs

Membres identifiés du Cancéropôle Est :
Dr QUIVRIN Magali

Tous les auteurs :
Corda H, Blanc-Lapierre A, Pigne G, Cartier L, Pasquier D, Ronchin P, Bera G, Hasbini A, Schipman B, Khalifa J, Sargos P, Quivrin M, Schick U, Mallet F, Laude C, Morand C, Loos G, Vaugier L, Mesgouez-Nebout N, Supiot S

Lien Pubmed

https://www.ncbi.nlm.nih.gov/pubmed/42140755

Résumé

/objective: Limited pelvic/para-aortic nodal relapse of prostate cancer after radical local treatment remains a major challenge for locoregional salvage strategies. Salvage Elective Nodes radiotherapy (ENRT) is an appealing option, but concerns persist regarding its toxicity. This study evaluates the 18-months toxicity profile of salvage ENRT combined with intermittent androgen deprivation therapy (iADT) in patients with pelvic and para-aortic oligometastatic disease, compared with iADT alone.